Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: A report of 16 cases and review of the literature

Joint Bone Spine

Volumn 80, Issue 2, 2013, Pages 178-182

  Ottaviani, Sébastien ^a   Brunier, Lauren ^a   Sibilia, Jean ^c   Maurier, François ^d   Ardizzone, Marc ^e   Wendling, Daniel ^f   Gill, Ghislaine ^a   Palazzo, Elisabeth ^a   Meyer, Olivier ^a   Dieudé, Philippe ^a,b  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d Service de médecine interne   (France)

^e CH de Mulhouse   (France)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Anakinra; Arthritis; Calcium pyrophosphate crystal; IL 1b

Indexed keywords

ANTIBIOTIC AGENT; CALCIUM PYROPHOSPHATE; COLCHICINE; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTHRITIS; ARTICLE; BACTERIAL PNEUMONIA; CALCIUM PYROPHOSPHATE CRYSTAL INDUCED ARTHRITIS; CLINICAL ARTICLE; COMORBIDITY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; PRESCRIPTION; RELAPSE; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; CALCIUM PYROPHOSPHATE; CHONDROCALCINOSIS; CRYSTALLIZATION; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; RETROSPECTIVE STUDIES;

EID: 84875517323     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.07.018     Document Type: Article

References (20)

1. Richette P., Bardin T., Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford) 2009, 48:711-715.
2. Filippucci E., Riveros M.G., Georgescu D., et al. Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study. Osteoarthritis Cartilage 2009, 17:178-181.
3. Filippucci E., Scire C.A., Delle Sedie A., et al. Ultrasound imaging for the rheumatologist. XXV. Sonographic assessment of the knee in patients with gout and calcium pyrophosphate deposition disease. Clin Exp Rheumatol 2010, 28:2-5.
4. Zhang W., Doherty M., Bardin T., et al. European League against rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011, 70:563-570.
5. Zhang W., Doherty M., Bardin T., et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
6. Terkeltaub R.A. Colchicine update: 2008. Semin Arthritis Rheum 2009, 38:411-419.
7. Park S.C., Chun H.J., Kang C.D., et al. Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury. World J Gastroenterol 2011, 17:4647-4653.
8. Brater D.C. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002, 32:33-42.
9. Martinon F., Petrilli V., Mayor A., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
10. Molto A., Olive A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine 2010, 77:102-107.
11. Gross O., Yazdi A.S., Thomas C.J., et al. Inflammasome activators induce interleukin-1 alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012, 36:388-400.
12. Chen K., Fields T., Mancuso C.A., et al. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010, 40:210-214.
13. So A., De Smedt T., Revaz S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
14. So A., De Meulemeester M., Pikhlak A., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064-3076.
15. Terkeltaub R., Sundy J.S., Schumacher H.R., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009, 68:1613-1617.
16. Announ N., Palmer G., Guerne P.A., et al. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 2009, 76:424-426.
17. McGonagle D., Tan A.L., Madden J., et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008, 58:631-633.
18. Couderc M, Mathieu S, Glace B., et al. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine 2012, 79:330-331.
19. Zhang W., Doherty M., Pascual E., et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011, 70:571-575.
20. Arend W.P., Malyak M., Guthridge C.J., et al. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998, 16:27-55.